Imprimis Pharma (IMMY) Misses Q2 EPS by 7c

Imprimis Pharma (NASDAQ: IMMY) reported Q2 EPS of ($0.39), $0.07 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $2 million versus the consensus estimate of $2.13 million.

For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
• Boston Omaha Corporation (BOC) Misses Q2 EPS by 2c